title: Hypocholesterolemic and immunostimulatory effects of orally applied Enterococcus faecium M-74 in man.
abstract: Lyophilized Enterococcus faecium M-74 was administered to 12 adult subjects in a daily oral dose of 5 x 10(9) bacteria for six weeks. The bacterium temporarily colonized the host intestine and its excretion with stool persisted for five weeks after the last does. The mean levels of serum cholesterol and LDL showed a a biphasic effect--an elevation followed by a sharp decrease (on day 64 of investigation). The decrease corresponded in time with a significant increase in the ability to reduce iodonitrotetrazolium and superoxide production by peripheral neutrophils incubated with zymosan or phorbol myristate acetate, and also with an elevated production of IgG by peripheral blood mononuclear cells. Hence, intake of E. faecium may have a hypocholesterolemic and immunostimulatory effect. It was also demonstrated that E. faecium significantly reduced the average activity of beta-D-glucuronidase in stools.
authors.affiliation: Department of Geriatrics, Faculty of Medicine, Bratislava, Slovakia.
authors.forename: A
authors.initials: A
authors.lastname: Mikes
authors.forename: M
authors.initials: M
authors.lastname: Ferencík
authors.forename: E
authors.initials: E
authors.lastname: Jahnová
authors.forename: L
authors.initials: L
authors.lastname: Ebringer
authors.forename: I
authors.initials: I
authors.lastname: Ciznár
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D016984:Enterococcus faecium / Q000276:immunology / Q000502:physiology; D005260:Female; D005612:Freeze Drying; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction; D016897:Respiratory Burst / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
chemical_list: D000276:Adjuvants, Immunologic; D000924:Anticholesteremic Agents; D007074:Immunoglobulin G; D008077:Lipoproteins, LDL; D015054:Zymosan; D002784:Cholesterol; D013755:Tetradecanoylphorbol Acetate